share_log

Lifecore Biomedical, Inc. - Common Stock's Return On Capital Employed Insights

Lifecore Biomedical, Inc. - Common Stock's Return On Capital Employed Insights

Lifecore Biomedical, Inc.-普通股的资本使用回报率见解
Benzinga ·  2023/03/20 22:49

Benzinga Pro data, Lifecore Biomedical, Inc. - Common Stock (NASDAQ:LFCR) reported Q2 sales of $38.80 million. Earnings fell to a loss of $12.45 million, resulting in a 3.19% decrease from last quarter. In Q1, Lifecore Biomedical, Inc. - Common Stock brought in $43.35 million in sales but lost $12.06 million in earnings.

Benzinga Pro 数据, Lifecore 生物医学公司——普通股 纳斯达克股票代码:LFCR)公布的第二季度销售额为3,880万美元。收益降至亏损1,245万美元,比上个季度下降3.19%。第一季度,Lifecore Biomedical, Inc.——普通股带来了4,335万美元的销售额,但收益损失了1,206万美元。

What Is ROCE?

什么是 ROCE?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Lifecore Biomedical, Inc. - Common Stock posted an ROCE of -0.17%.

资本使用回报率是衡量每年的税前利润相对于企业使用的资本的指标。收益和销售额的变化表明公司投资回报率的变化。更高的投资回报率通常代表公司的成功发展,也是未来每股收益更高的标志。低或负的投资回报率表明情况恰恰相反。在第二季度,Lifecore Biomedical, Inc.-普通股公布的投资回报率为-0.17%。

Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

请记住,尽管投资回报率可以很好地衡量公司近期业绩,但它并不是衡量公司在不久的将来的收益或销售额的高度可靠的预测指标。

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Lifecore Biomedical, Inc. - Common Stock is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

投资回报率是比较类似公司资本配置有效性的有力指标。相对较高的投资回报率表明Lifecore Biomedical, Inc.——普通股的运营效率可能高于该行业的其他公司。如果公司以目前的资本水平创造高额利润,则可以将其中一部分资金再投资于更多的资本,这通常会带来更高的回报,最终实现每股收益(EPS)的增长。

For Lifecore Biomedical, Inc. - Common Stock, a negative ROCE ratio of -0.17% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

对于Lifecore Biomedical, Inc.——普通股,负的投资回报率为-0.17%,表明管理层可能没有有效地配置资本。有效的资本配置是一个积极的指标,表明公司将取得更持久的成功和良好的长期回报;随着时间的推移,不良的资本配置可能会影响公司的业绩。

Analyst Predictions

分析师预测

Lifecore Biomedical, Inc. - Common Stock reported Q2 earnings per share at $-0.24/share, which did not meet analyst predictions of $0.03/share.

Lifecore Biomedical, Inc.——普通股公布的第二季度每股收益为-0.24美元,未达到分析师预测的每股0.03美元。

This article was generated by Benzinga's automated content engine and reviewed by an editor.

本文由Benzinga的自动内容引擎生成,并由编辑审阅。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发